Literature DB >> 12761118

Structural and functional consequences of cleavage of human secretory and human serum immunoglobulin A1 by proteinases from Proteus mirabilis and Neisseria meningitidis.

Adel Almogren1, Bernard W Senior, Lesley M Loomes, Michael A Kerr.   

Abstract

The cleavage of human serum monomeric immunoglobulin A1 (IgA1) and human secretory IgA1 (S-IgA1) by IgA1 proteinase of Neisseria meningitidis and cleavage by the proteinase from Proteus mirabilis have been compared. For serum IgA1, both proteinases cleaved only the alpha chain. N. meningitidis proteinase cleaved only in the hinge. P. mirabilis proteinase sequentially removed the tailpiece, the CH3 domain, and the CH2 domain. The cleavage of S-IgA1 by N. meningitidis proteinase occurred only in the hinge and was as rapid as that of serum IgA1. P. mirabilis proteinase predominantly cleaved the secretory component (SC) of S-IgA1. The SC of S-IgA1, whether cleaved or not, appeared to protect the alpha1 chain. Purified Fc fragment derived from the cleavage of serum IgA1 by N. meningitidis proteinase stimulated a respiratory burst in neutrophils through Fcalpha receptors, whereas the (Fcalpha1)(2)-SC fragment from digested S-IgA1 did not. The loss of the tailpiece from serum IgA1 treated with P. mirabilis proteinase had little effect, but the loss of the CH3 domain was concurrent with a rapid loss in the ability to bind to Fcalpha receptors. S-IgA1 treated with P. mirabilis proteinase under the same conditions retained the ability to bind to Fcalpha receptors. The results are consistent with the Fcalpha receptor binding site being at the CH2-CH3 interface. These data shed further light on the structure of S-IgA1 and indicate that the binding site for the Fcalpha receptor in S-IgA is protected by SC, thus prolonging its ability to activate phagocytic cells at the mucosal surface.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761118      PMCID: PMC155769          DOI: 10.1128/IAI.71.6.3349-3356.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human fcalpha receptor (FcalphaR) CD89.

Authors:  R J Pleass; J I Dunlop; C M Anderson; J M Woof
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

Review 2.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

3.  Proteinases of Proteus spp.: purification, properties, and detection in urine of infected patients.

Authors:  L M Loomes; B W Senior; M A Kerr
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Cleavage of the hormone human chorionic gonadotropin, by the Type 1 IgA1 protease of Neisseria gonorrhoeae, and its implications.

Authors:  B W Senior; W W Stewart; C Galloway; M A Kerr
Journal:  J Infect Dis       Date:  2001-08-29       Impact factor: 5.226

Review 6.  The IgA1 proteases of pathogenic bacteria.

Authors:  A G Plaut
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

7.  Comparative analysis of immunoglobulin A1 protease activity among bacteria representing different genera, species, and strains.

Authors:  J Reinholdt; M Kilian
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

8.  The special affinity of particular types of Proteus mirabilis for the urinary tract.

Authors:  B W Senior
Journal:  J Med Microbiol       Date:  1979-02       Impact factor: 2.472

9.  Proteus mirabilis strains of diverse type have IgA protease activity.

Authors:  B W Senior; M Albrechtsen; M A Kerr
Journal:  J Med Microbiol       Date:  1987-09       Impact factor: 2.472

10.  Urinary infection in boys.A three-year prospective study.

Authors:  R J Hallett; L Pead; R Maskell
Journal:  Lancet       Date:  1976-11-20       Impact factor: 79.321

View more
  7 in total

1.  Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease.

Authors:  Gestur Vidarsson; Natasja Overbeeke; Annette M Stemerding; Germie van den Dobbelsteen; Peter van Ulsen; Peter van der Ley; Mogens Kilian; Jan G J van de Winkel
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Application of comparative phylogenomics to study the evolution of Yersinia enterocolitica and to identify genetic differences relating to pathogenicity.

Authors:  Sarah L Howard; Michael W Gaunt; Jason Hinds; Adam A Witney; Richard Stabler; Brendan W Wren
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

3.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

4.  The nonplanar secretory IgA2 and near planar secretory IgA1 solution structures rationalize their different mucosal immune responses.

Authors:  Alexandra Bonner; Adel Almogren; Patricia B Furtado; Michael A Kerr; Stephen J Perkins
Journal:  J Biol Chem       Date:  2008-12-23       Impact factor: 5.157

Review 5.  Pathogenesis of Proteus mirabilis Infection.

Authors:  Chelsie E Armbruster; Harry L T Mobley; Melanie M Pearson
Journal:  EcoSal Plus       Date:  2018-02

6.  A comparison of the binding of secretory component to immunoglobulin A (IgA) in human colostral S-IgA1 and S-IgA2.

Authors:  Adel Almogren; Bernard W Senior; Michael A Kerr
Journal:  Immunology       Date:  2006-11-29       Impact factor: 7.397

7.  IgA as a potential candidate for enteric monoclonal antibody therapeutics with improved gastrointestinal stability.

Authors:  Aaron L Wallace; Matthew I Schneider; Jacqueline R Toomey; Ryan M Schneider; Mark S Klempner; Yang Wang; Lisa A Cavacini
Journal:  Vaccine       Date:  2020-10-08       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.